B. Riley Securities raised the price target for the Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) stock to “a Buy”. The rating was released on February 18, 2021. The research report from Citigroup has upgraded the stock from Neutral to Buy, with a price target set at $23. The stock was downgraded by H.C. Wainwright, who disclosed in a research note on May 22, 2020, from Buy to Neutral and set the price objective to $15.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Historical Earnings Surprises and Revenue Forecasts
Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of -$0.44 during the last quarter as opposed to a consensus estimate of -$0.49, which indicates the company beat its estimate by $0.05, which implies that the company surprised the market by 10.20%. It appears that the average earnings per share estimate for the current quarter (ending in Mar 2021) is -$0.64. This is an average of 5 analysts’ earnings, where the high earnings per share estimate is -$0.58 and the low earnings per share estimate is -$0.7.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) dipped -30.75% to close Tuesday’s market session at $13.42, lower as compared to yesterday’s close. The stock price fluctuated between $13.15 and $17.66 throughout the trading session with the volume trading being 8132997 shares, which represented a significant variation when compared to the three months average volume of 707.23K shares. The firm’s stock price fluctuated -34.85% within the last five trades and -41.50% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -23.75% in the last 6 months and -43.83% was subtracted to its value over the previous 3 months. SNDX stock is trading at a margin of -40.43%, -40.89% and -31.72% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, SNDX deals in the Healthcare domain. The stock is trading -51.81 percent below its 52-week high and 31.57 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -4.03. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Syndax Pharmaceuticals Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $665.36 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 443.58 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 2.45, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Egros Fabrice, the Director at Syndax Pharmaceuticals Inc. (SNDX) has sold 10,241 shares of firm on Mar 01 at a price of $24.31 against the total amount of $0.25 million. In another inside trade, Morrison Briggs, Chief Executive Officer of Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) sold 35,156 shares of the firm on Feb 08 for a total worth of $0.72 million at a price of $20.55. An inside trade which took place on Feb 01, President and COO of Syndax Pharmaceuticals Inc. Metzger Michael A sold 15,000 shares of firm against total price of $0.3 million at the cost of $20.19 per share.